Irritable bowel syndrome diarrhea dominant. Irritable bowel syndrome with diarrhea
Conditions
Interventions
Intervention 1: Intervention Group: Mebeverine Tablet, 135 milligram twice a day in combination with 1 sachet of Luvos®Healing Earth twice a day . Intervention 2: Control group: Mebeverine Tablet, 135
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: All patients with diarrhea dominant irritable bowel syndrome based on Rome's criteria 4(at least 1 time per week abdominal pain related to defication and 2 of the other criteria at least in 1/4 of defication :stool frequency>3 /day,abnormal loose stool form ,defecatory urgency, mucus with bowel movements) age beween 18-65 years old
Exclusion criteria
Exclusion criteria: Lactase deficiency Celiac disease Inflammatory bowel disease Food allergy Peregnancy Systemic disease(Diabetes Melitous,Hypertention, Cardiac ,Pulmonary ,Renal,liver,Thyroid disease, Cancer,Myopathy, Neuropathy, Sclerodermia) History of abdominal surgery History of allergy to periscribed medication Non-compliant and uncooperative
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life in patients with Irritable Bowel syndrome diarrhea dominant. Timepoint: before intervention and 2, 4 weeks after intervention. Method of measurement: Quality of Life questionnaire.;Symptoms in patients with Irritable Bowel syndrome diarrhea dominant. Timepoint: before intervention and 2, 4 , 6 weeks after intervention. Method of measurement: Symptom severity score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance rate. Timepoint: 2 and 4 weeks after intervention. Method of measurement: Data gathering sheet.;Adverse effect rate. Timepoint: 2 and 4 weeks after intervention. Method of measurement: Data gathering sheet. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Mokhtare
Iran University of Medical Sciences
Outcome results
None listed